Perspective Therapeutics提交8-K,披露VMT01临床试验中期结果更新
Perspective Therapeutics, Inc. (0000728387) (Filer)
Perspective Therapeutics于11月6日提交8-K,称已发布新闻稿并公布海报,介绍VMT01([²¹²Pb]lapemelanotide zapixetar)1/2a期临床试验的更新中期结果。试验面向肿瘤表达黑皮质素1受体、不可切除或转移性黑色素瘤患者,结果在免疫治疗学会第41届年会上展示。
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 06, 2026 |
Perspective Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
Delaware |
001-33407 |
41-1458152 |
||
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
c/o Perspective Therapeutics, Inc. 2401 Elliott Avenue Suite 320 |
||||
Seattle, Washington |
98121 |
|||
(Address of Principal Executive Offices) |
(Zip Code) |
|||
Registrant’s Telephone Number, Including Area Code: (206) 676-0900 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
Trading |
|
||
Common Stock, $0.001 par value |
CATX |
NYSE American LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On November 6, 2026, Perspective Therapeutics, Inc. (the “Company”) issued a press release and posted to its website a poster presentation announcing updated interim results from the Company’s Phase 1/2a clinical trial of [212Pb]lapemelanotide zapixetar (VMT01) for the diagnosis and treatment of patients with unresectable or metastatic melanoma who have demonstrated melanocortin 1 receptor tumor expression that are being presented at the 41st Annual Meeting of the Society for Immunotherapy of Cancer taking place November 4-8, 2026 in Phoenix, Arizona. A copy of the press release is filed herewith as Exhibit 99.1, and a copy of the poster presentation is filed herewith as Exhibit 99.2, and each is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. |
Description |
|
99.1 |
||
99.2 |
||
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PERSPECTIVE THERAPEUTICS, INC. |
|||
Date: |
November 6, 2026 |
By: |
/s/ Johan (Thijs) Spoor |
Johan (Thijs) Spoor |
来源:SEC EDGAR · 本站存档